Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot(Centre National de la Recherche Scientifique), David Tulasne(Institut Pasteur de Lille)
Cited by 121
Related Papers
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
|Annals of Oncology|2023|69
Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
|Cancer Research|2014|68
ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease
|EBioMedicine|2016|52